Standout Papers

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma 2012 2026 2016 2021 988
  1. Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma (2012)
    Aleksandar Sekulić, Michael R. Migden et al. New England Journal of Medicine
  2. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma (2017)
    Jason Chesney, Igor Puzanov et al. Journal of Clinical Oncology

Immediate Impact

11 by Nobel laureates 18 from Science/Nature 72 standout
Sub-graph 1 of 20

Citing Papers

Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Therapeutic cancer vaccines
2021 Standout
10 intermediate papers

Works of Philip Friedlander being referenced

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial
2018
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
2016
and 5 more

Author Peers

Author Last Decade Papers Cites
Philip Friedlander 2046 2200 714 60 3.7k
Christopher Brooks 2885 3579 595 85 5.2k
Barry M. Kacinski 1259 1634 1186 94 4.0k
Gary D. Shipley 1479 3147 578 48 5.7k
Lyn M. Duncan 1752 1625 678 41 3.2k
William Damsky 1531 1808 1387 122 4.5k
Walter C. Darbonne 1836 2675 1528 46 6.1k
Klaus Griewank 2383 1980 1686 81 5.1k
Stephen E. Gould 1758 3924 453 47 5.2k
Uwe Trefzer 2653 2804 1082 76 4.4k
Eddy C. Hsueh 2931 1533 2429 95 4.9k

All Works

Loading papers...

Rankless by CCL
2026